186 related articles for article (PubMed ID: 34067960)
1. Precision Therapy for Mesothelioma: Feasibility and New Opportunities.
Dulloo S; Bzura A; Fennell DA
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067960
[TBL] [Abstract][Full Text] [Related]
2. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
Sekido Y
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565815
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
5. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
Illei PB; Rusch VW; Zakowski MF; Ladanyi M
Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
[TBL] [Abstract][Full Text] [Related]
6. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
7. Genomic Landscape of Malignant Mesotheliomas.
Kato S; Tomson BN; Buys TP; Elkin SK; Carter JL; Kurzrock R
Mol Cancer Ther; 2016 Oct; 15(10):2498-2507. PubMed ID: 27507853
[TBL] [Abstract][Full Text] [Related]
8. Malignant mesothelioma in situ.
Churg A; Hwang H; Tan L; Qing G; Taher A; Tong A; Bilawich AM; Dacic S
Histopathology; 2018 May; 72(6):1033-1038. PubMed ID: 29350783
[TBL] [Abstract][Full Text] [Related]
9. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
10. A mouse model recapitulating molecular features of human mesothelioma.
Altomare DA; Vaslet CA; Skele KL; De Rienzo A; Devarajan K; Jhanwar SC; McClatchey AI; Kane AB; Testa JR
Cancer Res; 2005 Sep; 65(18):8090-5. PubMed ID: 16166281
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Bueno R; Stawiski EW; Goldstein LD; Durinck S; De Rienzo A; Modrusan Z; Gnad F; Nguyen TT; Jaiswal BS; Chirieac LR; Sciaranghella D; Dao N; Gustafson CE; Munir KJ; Hackney JA; Chaudhuri A; Gupta R; Guillory J; Toy K; Ha C; Chen YJ; Stinson J; Chaudhuri S; Zhang N; Wu TD; Sugarbaker DJ; de Sauvage FJ; Richards WG; Seshagiri S
Nat Genet; 2016 Apr; 48(4):407-16. PubMed ID: 26928227
[TBL] [Abstract][Full Text] [Related]
12. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
14. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
15. Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma.
Shrestha R; Nabavi N; Volik S; Anderson S; Haegert A; McConeghy B; Sar F; Brahmbhatt S; Bell R; Le Bihan S; Wang Y; Collins C; Churg A
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545767
[TBL] [Abstract][Full Text] [Related]
16. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
18. [Molecular heterogeneity of malignant pleural mesotheliomas].
Tranchant R; Montagne F; Jaurand MC; Jean D
Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
[TBL] [Abstract][Full Text] [Related]
19. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.
Yang H; Xu D; Schmid RA; Peng RW
Ther Adv Med Oncol; 2020; 12():1758835920971421. PubMed ID: 33240401
[TBL] [Abstract][Full Text] [Related]
20. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]